These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10926890)

  • 1. Description of a computer program to assess cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen information during monitoring of metastatic breast cancer.
    Sölétormos G; Schiøler V
    Clin Chem; 2000 Aug; 46(8 Pt 1):1106-13. PubMed ID: 10926890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA.
    Sölétormos G; Nielsen D; Schiøler V; Mouridsen H; Dombernowsky P
    Eur J Cancer; 2004 Mar; 40(4):481-6. PubMed ID: 14962712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
    Sölétormos G; Petersen PH; Dombernowsky P
    Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up.
    Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P
    Clin Chem; 1996 Apr; 42(4):564-75. PubMed ID: 8605674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
    Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
    Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of serum tumor markers for the diagnosis and follow-up of breast cancer.
    Barrenetxea G; Schneider J; Llorente MF
    Oncology; 1998; 55(5):447-9. PubMed ID: 9732223
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.
    Bottini A; Berruti A; Tampellini M; Morrica B; Brunelli A; Gnocchi E; Brizzi MP; Aguggini S; Fara E; Alquati P; Dogliotti L
    Tumour Biol; 1997; 18(5):301-10. PubMed ID: 9276030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum concentration of selected neoplasm markers: CA15-3, TPS and CEA in women with diagnosed breast benign disease].
    Kochańska-Dziurowicz A; Pasich R; Stanjek A; Gaweł-Szostek V; Jankowski T
    Ginekol Pol; 2000 Sep; 71(9):1139-43. PubMed ID: 11082991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression criteria for cancer antigen 15.3 and carcinoembryonic antigen in metastatic breast cancer compared by computer simulation of marker data.
    Sölétormos G; Hyltoft Petersen P; Dombernowsky P
    Clin Chem; 2000 Jul; 46(7):939-49. PubMed ID: 10894837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Distler W
    Clin Chem Lab Med; 1998 Nov; 36(11):841-6. PubMed ID: 9877089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
    Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations.
    Nicolini A; Carpi A; Ferrari P; Pieri L
    Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts.
    Nicolini A; Carpi A; Ferrari P; Anselmi L
    Int J Biol Markers; 1997; 12(4):181-6. PubMed ID: 9582609
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study.
    Nicolini A; Carpi A; Ferrari P; Rossi G
    Cancer Lett; 2008 May; 263(1):122-9. PubMed ID: 18241981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
    Buccheri G; Ferrigno D
    J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
    Hu XC; Day W; Jones B; Loo WT; Chow LW
    Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer.
    Tuxen MK; Sölétormos G; Petersen PH; Dombernowsky P
    Clin Chem Lab Med; 2001 Jun; 39(6):531-8. PubMed ID: 11506467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TPA and CA 15.3 measurements for breast cancer monitoring in a routine setting.
    Bonfrer JM; Korse CM
    Int J Biol Markers; 1999; 14(1):40-4. PubMed ID: 10367249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.